The business objective of any BioIT company is to support the pharma companies, which are under tremendous pressure due to rising R&D costs, drying of product pipeline and regulatory hurdles. Companies, such as Strand Life Sciences and CellWorks, have been working towards meeting this aim.
![](http://www.biospectrumindia.com/images/content/2011/oct/CSO.png)
In this issue of CSO series, we focus on the contributions of
Dr Kalyanasundaram Subramanian, CSO, Strand Life Sciences, and
Dr Shireen Vali, CSO, CellWorks, towards development of technology-based solutions to enable drug discovery R&D, improve productivity and success rate of the process, reduce costs, increase efficiency, and identify potential side-effects.